Abstract:BackgroundThe diversity of clinical tumor profiling approaches (small panels to whole exomes with matched or unmatched germline analysis) may engender uncertainty about their benefits and liabilities, particularly in light of reported germline false positives in tumor-only profiling and use of global mutational and/or neoantigen data. The goal of this study was to determine the impact of genomic analysis strategies on error rates and data interpretation across contexts and ancestries.MethodsWe modeled common t… Show more
“…WES and WGS will likely be most useful for determining factors that may indicate response to immunotherapy, such as predicted formation of neoantigens [48]. While these techniques also offer a highly accurate measure of mutational burden, it has recently been shown that NGS panels may suffice for this [49, 50]. Tarczy-Hornoch et al [51] have surveyed potential methods for properly integrating WES and WGS information within EHRs.…”
Section: Current Status Of Genomic and Related Informationmentioning
The rise of genomically targeted therapies and immunotherapy has revolutionized the practice of oncology in the last 10–15 years. At the same time, new technologies and the electronic health record (EHR) in particular have permeated the oncology clinic. Initially designed as billing and clinical documentation systems, EHR systems have not anticipated the complexity and variety of genomic information that needs to be reviewed, interpreted, and acted upon on a daily basis. Improved integration of cancer genomic data with EHR systems will help guide clinician decision making, support secondary uses, and ultimately improve patient care within oncology clinics. Some of the key factors relating to the challenge of integrating cancer genomic data into EHRs include: the bioinformatics pipelines that translate raw genomic data into meaningful, actionable results; the role of human curation in the interpretation of variant calls; and the need for consistent standards with regard to genomic and clinical data. Several emerging paradigms for integration are discussed in this review, including: non-standardized efforts between individual institutions and genomic testing laboratories; “middleware” products that portray genomic information, albeit outside of the clinical workflow; and application programming interfaces that have the potential to work within clinical workflow. The critical need for clinical-genomic knowledge bases, which can be independent or integrated into the aforementioned solutions, is also discussed.Electronic supplementary materialThe online version of this article (doi:10.1186/s13073-016-0371-3) contains supplementary material, which is available to authorized users.
“…WES and WGS will likely be most useful for determining factors that may indicate response to immunotherapy, such as predicted formation of neoantigens [48]. While these techniques also offer a highly accurate measure of mutational burden, it has recently been shown that NGS panels may suffice for this [49, 50]. Tarczy-Hornoch et al [51] have surveyed potential methods for properly integrating WES and WGS information within EHRs.…”
Section: Current Status Of Genomic and Related Informationmentioning
The rise of genomically targeted therapies and immunotherapy has revolutionized the practice of oncology in the last 10–15 years. At the same time, new technologies and the electronic health record (EHR) in particular have permeated the oncology clinic. Initially designed as billing and clinical documentation systems, EHR systems have not anticipated the complexity and variety of genomic information that needs to be reviewed, interpreted, and acted upon on a daily basis. Improved integration of cancer genomic data with EHR systems will help guide clinician decision making, support secondary uses, and ultimately improve patient care within oncology clinics. Some of the key factors relating to the challenge of integrating cancer genomic data into EHRs include: the bioinformatics pipelines that translate raw genomic data into meaningful, actionable results; the role of human curation in the interpretation of variant calls; and the need for consistent standards with regard to genomic and clinical data. Several emerging paradigms for integration are discussed in this review, including: non-standardized efforts between individual institutions and genomic testing laboratories; “middleware” products that portray genomic information, albeit outside of the clinical workflow; and application programming interfaces that have the potential to work within clinical workflow. The critical need for clinical-genomic knowledge bases, which can be independent or integrated into the aforementioned solutions, is also discussed.Electronic supplementary materialThe online version of this article (doi:10.1186/s13073-016-0371-3) contains supplementary material, which is available to authorized users.
“…Recent work has shown that mutational load and neoantigen load might be more useful biomarkers of response than specific driver gene mutations [47]. Similarly, the determination of mutational load and neoantigen expression is more predictive when whole exome data are used compared to large or small gene panels [48]. …”
Section: Matching the Test To The Intended Usementioning
confidence: 99%
“…Some groups do not use matched normal material. In order to minimize false-positive calls, these groups either focus on calling previously characterized driver events in known oncogenes (in the case of hotspot panels), or use advanced filtering methods—unmatched normal, PoN, large germline databases (for example, 1000 Genomes, ExAc)—to remove non-somatic variants [48]. Specificity can be further increased by review of candidate mutations by an experienced molecular pathologist and cross-referencing somatic mutation databases such as COSMIC for pathogenicity information [48].…”
Technological, methodological, and analytical advances continue to improve the resolution of our view into the cancer genome, even as we discover ways to carry out analyses at greater distances from the primary tumor sites. These advances are finally making the integration of cancer genomic profiling into clinical practice feasible. Formalin fixation and paraffin embedding, which has long been the default pathological biopsy medium, is now being supplemented with liquid biopsy as a means to profile the cancer genomes of patients. At each stage of the genomic data generation process—sample collection, preservation, storage, extraction, library construction, sequencing, and variant calling—there are variables that impact the sensitivity and specificity of the analytical result and the clinical utility of the test. These variables include sample degradation, low yields of nucleic acid, and low variant allele fractions (proportions of assayed molecules carrying variant allele(s)). We review here the most common pre-analytical and analytical factors relating to routine cancer patient genome profiling, some solutions to common challenges, and the major sample preparation and sequencing technology choices available today.
“…Furthermore, although the molecular landscapes of many cancers have been revealed using precision oncology approaches, many of the alterations observed in patients remain undruggable, and viable targets are incompletely characterized. In addition, a considerable amount of diversity exists regarding the types of molecular tests being offered clinically [8]; combined with the knowledge gap regarding the interpretation of genomic test results within the field of clinical oncology, this diversity has fostered confusion among physicians about the meaning and the clinical utility of genomic data at the point of care [9]. Perhaps most critically, prospective trials of molecular profiling across cancers in an unselected manner are not yet mature.…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.